Delcath Systems, Inc.

NASDAQ:DCTH

10.5 (USD) • At close November 1, 2024
Bedrijfsnaam Delcath Systems, Inc.
Symbool DCTH
Munteenheid USD
Prijs 10.5
Beurswaarde 294,008,400
Dividendpercentage 0%
52-weken bereik 2.25 - 11.745
Industrie Medical Devices
Sector Healthcare
CEO Mr. Gerard J. Michel MBA, MS
Website https://www.delcath.com

An error occurred while fetching data.

Over Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and

Vergelijkbare Aandelen

Check-Cap Ltd. logo

Check-Cap Ltd.

CHEK

1.15 USD

Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc.

CABA

3.71 USD

Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp.

TNXP

0.139 USD

Immunome, Inc. logo

Immunome, Inc.

IMNM

11.59 USD

Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

TARA

2.47 USD

X4 Pharmaceuticals, Inc. logo

X4 Pharmaceuticals, Inc.

XFOR

0.519 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)